Biomarkers of aging with prognostic and predictive value in non-oncological diseases.
In this review we discuss the current knowledge on Biomarkers of Aging (BoAs) in the context of human diseases and their value as predictive or prognostic markers. The vast majority of studies using BoAs in a clinical context have been undertaken by determining telomere length in peripheral blood mononuclear cells (PBMCs), whereas the expression of cell cycle inhibitors and an increase in advanced glycation end products (AGEs) have rarely been used. Here we summarize the impact of BoAs on non-oncological, hematological, cardiovascular, metabolic, renal and neurological diseases, as well as on overall survival. The specific methodologies utilized are described and evaluated for their high-throughput potential.
Koppelstaetter
Christian
C
Anichstrasse 35, A-6020 Innsbruck, Austria. gert.mayer@i-med.ac.at.
Kern
Georg
G
Mayer
Gert
G
D000375:Aging / Q000235:genetics*; D000741:Anemia, Aplastic / Q000235:genetics; D015415:Biomarkers / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000235:genetics; D003704:Dementia / Q000235:genetics; D003920:Diabetes Mellitus / Q000235:genetics; D042241:Early Diagnosis; D006801:Humans; D007674:Kidney Diseases / Q000235:genetics; D010024:Osteoporosis / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D016615:Telomere / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D015415:Biomarkers